Intramuscular Dermatan Sulfate MF701 in Patients with Hip Fracture: Relationship between Pharmacokinetics and Antithrombotic Efficacy

Summary

Two groups of 23 and 84 patients with hip fracture received intramuscularly 100 and 300 mg dermatan sulfate (MF701) b. i. d., respectively, for the prophylaxis of deep vein thrombosis. Median duration of treatment was 17 and 16 days, respectively. Four blood samples were collected from each patient while under treatment. Plasma levels of dermatan sulfate were determined by a chromogenic substrate assay. A one-compartment model for multiple doses was employed to estimate the pharmacokinetic parameters. Fitting was applied to mean plasma concentrations calculated for each sampling time and weighted according to the number of samples available at each time. Thrombin clotting time was measured on the same plasma samples. Antithrombotic efficacy was assessed by bilateral venography.

Plasma levels of dermatan sulfate increased gradually throughout the treatment, indicating a marked accumulation process. Time to reach steady-state was 14 or 9 days with 100 or 300 mg b. i. d., respectively. This was due to an apparent prolonged terminal half-life (68 or 43 h), which actually reflected slow absorption from the injection sites. The clinical efficacy of MF701 in preventing DVT was found to be dependent on the plasma concentration of the drug and also, but less significantly, on the prolongation of thrombin clotting time. Dermatan sulfate plasma levels greater than 9 μ/ml are advisable to optimize efficacy in hip fracture patients.

• References

• 1 Tollefsen DM. Heparin Cofactor II.. In: Lane DA, Lindahl U. (eds) Heparin: Clinical and Biological Properties: Clinical Applications. Edward Arnold; London: 1989: 257-74
• 2 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-17
• 3 Cofrancesco E, Colombi M, Gianese F, Cortellaro M. The effect of dermatan sulfate on “in vitro” human plasma coagulation platelet aggregation and β-TG/PF4 release. Thromb Res 1990; 57: 405-14
• 4 Sié P, Dupouy D, Dol F, Boneu B. Determination of plasma dermatan sulfate at relevant pharmacological concentrations. Semin Thromb Hemost 1991; 17 (Suppl 2) 181-5
• 5 Maggi A, Abbadini N, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 1987; 17: 329-35
• 6 Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 1989; 61: 7-9
• 7 Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. Effects of dermatan sulfate and heparin on inhibition of thrombus growth “in vivo’'. Ann NY AcadSci 1989; 556: 304-312
• 8 Agnelli G, Cosmi B, Di Filippo P, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupattelli L, Rinonapoli E, Nenci GG. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 67: 203-208
• 9 Prandoni P, Meduri F, Cuppini S, Toniato A, Zangrandi F, Polistena P, Gianese F, Maffei Faccioli A. Dermatan sulfate: a safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 1992; 79: 505-509
• 10 Cohen AT, Phillips MJ, Edmonson RA, Melissari E, Vaidyanathan I, Kakkar VV. Dermatan sulphate for prophylaxis of deep vein thrombosis in elective hip surgery: a dose-finding trial. Thromb Haemost 1993; 69: 621 (Abstr 280)
• 11 Dawes J, Hodson BA, Pepper DS. The absorption clearance and metabolic fate of dermatan sulfate administered to man. Studies using a radioiodinated derivative. Thromb Haemost 1989; 62: 945-949
• 12 Agnelli G, Cosmi B, Renga C, Federici F, Nenci GG, Houin G, Gianese F. Human pharmacokinetics and pharmacodynamics of MF701 dermatan sulfate administered by continuous intravenous infusion. Thromb Haemost 1990; 64: 256-259
• 13 Dol F, Houin G, Rostin M, Montastruc JL, Dupouy D, Gianese F, Sié P, Boneu B. Pharmacokinetics and pharmacodynamics of dermatan sulfate in man. Blood 1989; 74: 1577-1582
• 14 Dawes J, McLaren M, Forbes C, Belch JJF, Lane DA, Bray B, McEwen J, Houin G, Gianese F. The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers. Br J Clin Pharmac 1991; 32: 361-366
• 15 Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmac 1991; 32: 669-670
• 16 Imbimbo BP. A simple method for analysing large number of sparse plasma concentration data. Eur J Drug Metab Pharmacokinet 1993; 18 (Suppl 1) 193 (A 362)
• 17 Dupouy D, Sié P, Dol F, Boneu B. A simple method to measure dermatan sulfate at submicrogram concentrations in plasma. Thromb Haemost 1988; 60: 236-239
• 18 Collins BT. Pharmacokinetic models. In: Handbook of in Vivo Toxicity Testing. Clayson DB, Krewski DR. (eds) Press Inc; New York: 1990: 339-382
• 19 Imbimbo BP, Imbimbo E, Daniotti S, Verotta D, Bassotti G. A new criterion for selection of pharmacokinetic multiexponential equations. J Pharmac Sci 1988; 77: 784-9
• 20 Heinzel G. Salient points of various programs: TOPFIT. In: Pharmacokinetics During Drug Development: Data Analysis and Evaluation Techniques Bozler G, van Rossum JM. (eds). Fischer Verlag; Stuttgart: 1982
• 21 Chan KKH, Gibaldi M. Assessment of drug absorption after oral administration. J Phar Sci 1985; 74: 388-393
• 22 Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993; 23 (Suppl) 89-98